IL2 and idiopathic nephrotic syndrome: An open-label case-control phase 1–2 pilot trial was designed to assess safety and clinical and immunologic effects of repeated administration of recombinant low dose IL2 in 5 patients with idiopathic nephrotic syndrome unresponsive to all treatments used for this condition.